Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Breast Cancer Reports
Erschienen in: Current Breast Cancer Reports 2/2017

18.04.2017 | Local-Regional Evaluation and Therapy (EP Mamounas, Section Editor)

New Insights on the Role of Surgery for the Breast Primary Tumor in Patients Presenting With Stage IV Disease

verfasst von: Anvy Nguyen, Tari A. King

Erschienen in: Current Breast Cancer Reports | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Though systemic therapy has been the standard treatment for patients with de novo metastatic breast cancer, a large number of retrospective studies demonstrate that resection of the primary tumor is associated with improved survival. Here, we review the potential rationale for resection, available retrospective and prospective data, and challenges in applying these data in clinical practice.

Recent Findings

Results from prospective trials to date are limited. The only published randomized controlled trial concluded that locoregional therapy for the primary tumor did not result in improved overall survival and was associated with shorter distant progression-free survival.

Summary

Recommendations regarding the potential survival advantage of locoregional therapy cannot be firmly made until additional results from prospective trials are available. Systemic therapy remains first-line treatment, and surgical resection of the primary tumor should only be considered for select patients after a full discussion of the limitations of the current data.
Literatur
1.
Howlader N, Ries LA, Stinchcomb DG, Edwards BK. The impact of underreported Veterans Affairs data on national cancer statistics: analysis using population-based SEER registries. J Natl Cancer Inst. 2009;101:533–6.CrossRefPubMedPubMedCentral
2.
Ly BH, Nguyen NP, Vinh-Hung V, et al. Loco-regional treatment in metastatic breast cancer patients: is there a survival benefit? Breast Cancer Res Treat. 2010;119:537–45.CrossRefPubMed
3.
Dawood S, Broglio K, Ensor J, et al. Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol. 2010;21:2169–74.CrossRefPubMedPubMedCentral
4.
Lobbezoo DJ, van Kampen RJ, Voogd AC, et al. Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer? Br J Cancer. 2015;112:1445–51.CrossRefPubMedPubMedCentral
5.
Staren ED, Salerno C, Rongione A, et al. Pulmonary resection for metastatic breast cancer. Arch Surg. 1992;127:1282–4.CrossRefPubMed
6.
Meimarakis G, Ruttinger D, Stemmler J, et al. Prolonged overall survival after pulmonary metastasectomy in patients with breast cancer. Ann Thorac Surg. 2013;95:1170–80.CrossRefPubMed
7.
Adam R, Aloia T, Krissat J, et al. Is liver resection justified for patients with hepatic metastases from breast cancer? Ann Surg. 2006;244:897–907. discussion 907-898CrossRefPubMedPubMedCentral
8.
Friedel G, Pastorino U, Ginsberg RJ, et al. Results of lung metastasectomy from breast cancer: prognostic criteria on the basis of 467 cases of the International Registry of Lung Metastases. Eur J Cardiothorac Surg. 2002;22:335–44.CrossRefPubMed
9.
Friedel G, Linder A, Toomes H. The significance of prognostic factors for the resection of pulmonary metastases of breast cancer. Thorac Cardiovasc Surg. 1994;42:71–5.CrossRefPubMed
10.
Milano MT, Katz AW, Zhang H, Okunieff P. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys. 2012;83:878–86.CrossRefPubMed
11.
Milano MT, Zhang H, Metcalfe SK, et al. Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy. Breast Cancer Res Treat. 2009;115:601–8.CrossRefPubMed
12.
Kobayashi T, Ichiba T, Sakuyama T, et al. Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review. Breast Cancer. 2012;19:218–37.CrossRefPubMed
13.
Pockaj BA, Wasif N, Dueck AC, et al. Metastasectomy and surgical resection of the primary tumor in patients with stage IV breast cancer: time for a second look? Ann Surg Oncol. 2010;17:2419–26.CrossRefPubMedPubMedCentral
14.
15.
Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358:966–70.CrossRefPubMed
16.
Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655–9.CrossRefPubMed
17.
Rosen SA, Buell JF, Yoshida A, et al. Initial presentation with stage IV colorectal cancer: how aggressive should we be? Arch Surg. 2000;135:530–4. discussion 534-535CrossRefPubMed
18.
Hallissey MT, Allum WH, Roginski C, Fielding JW. Palliative surgery for gastric cancer. Cancer. 1988;62:440–4.CrossRefPubMed
19.
Essner R, Lee JH, Wanek LA, et al. Contemporary surgical treatment of advanced-stage melanoma. Arch Surg. 2004;139:961–6. discussion 966-967CrossRefPubMed
20.
Fehm T, Sagalowsky A, Clifford E, et al. Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res. 2002;8:2073–84.PubMed
21.
Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781–91.CrossRefPubMed
22.
Budd GT, Cristofanilli M, Ellis MJ, et al. Circulating tumor cells versus imaging—predicting overall survival in metastatic breast cancer. Clin Cancer Res. 2006;12:6403–9.CrossRefPubMed
23.
Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5:275–84.CrossRefPubMed
24.
Li X, Lewis MT, Huang J, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008;100:672–9.CrossRefPubMed
25.
26.
Danna EA, Sinha P, Gilbert M, et al. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res. 2004;64:2205–11.CrossRefPubMed
27.
Prehn RT. Two competing influences that may explain concomitant tumor resistance. Cancer Res. 1993;53:3266–9.PubMed
28.
Coffey JC, Wang JH, Smith MJ, et al. Excisional surgery for cancer cure: therapy at a cost. Lancet Oncol. 2003;4:760–8.CrossRefPubMed
29.
Demicheli R, Retsky MW, Hrushesky WJ, et al. The effects of surgery on tumor growth: a century of investigations. Ann Oncol. 2008;19:1821–8.CrossRefPubMed
30.
Retsky M, Bonadonna G, Demicheli R, et al. Hypothesis: induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patients. Breast Cancer Res. 2004;6:R372–4.CrossRefPubMedPubMedCentral
31.
O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994;79:315–28.CrossRefPubMed
32.
ten Kate M, Hofland LJ, van Grevenstein WM, et al. Influence of proinflammatory cytokines on the adhesion of human colon carcinoma cells to lung microvascular endothelium. Int J Cancer. 2004;112:943–50.CrossRefPubMed
33.
Benish M, Bartal I, Goldfarb Y, et al. Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann Surg Oncol. 2008;15:2042–52.CrossRefPubMed
34.
Babiera GV, Rao R, Feng L, et al. Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol. 2006;13:776–82.CrossRefPubMed
35.
Bafford AC, Burstein HJ, Barkley CR, et al. Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival. Breast Cancer Res Treat. 2009;115:7–12.CrossRefPubMed
36.
Blanchard DK, Shetty PB, Hilsenbeck SG, Elledge RM. Association of surgery with improved survival in stage IV breast cancer patients. Ann Surg. 2008;247:732–8.CrossRefPubMed
37.
Cady B, Nathan NR, Michaelson JS, et al. Matched pair analyses of stage IV breast cancer with or without resection of primary breast site. Ann Surg Oncol. 2008;15:3384–95.CrossRefPubMed
38.
Dominici L, Najita J, Hughes M, et al. Surgery of the primary tumor does not improve survival in stage IV breast cancer. Breast Cancer Res Treat. 2011;129:459–65.CrossRefPubMedPubMedCentral
39.
Fields RC, Jeffe DB, Trinkaus K, et al. Surgical resection of the primary tumor is associated with increased long-term survival in patients with stage IV breast cancer after controlling for site of metastasis. Ann Surg Oncol. 2007;14:3345–51.CrossRefPubMed
40.
Gnerlich J, Jeffe DB, Deshpande AD, et al. Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988-2003 SEER data. Ann Surg Oncol. 2007;14:2187–94.CrossRefPubMed
41.
Hazard HW, Gorla SR, Scholtens D, et al. Surgical resection of the primary tumor, chest wall control, and survival in women with metastatic breast cancer. Cancer. 2008;113:2011–9.CrossRefPubMed
42.
Khan SA, Stewart AK, Morrow M. Does aggressive local therapy improve survival in metastatic breast cancer? Surgery. 2002;132:620–6. discussion 626-627CrossRefPubMed
43.
Le Scodan R, Stevens D, Brain E, et al. Breast cancer with synchronous metastases: survival impact of exclusive locoregional radiotherapy. J Clin Oncol. 2009;27:1375–81.CrossRefPubMed
44.
Leung AM, Vu HN, Nguyen KA, et al. Effects of surgical excision on survival of patients with stage IV breast cancer. J Surg Res. 2010;161:83–8.CrossRefPubMed
45.
Neuman HB, Morrogh M, Gonen M, et al. Stage IV breast cancer in the era of targeted therapy: does surgery of the primary tumor matter? Cancer. 2010;116:1226–33.CrossRefPubMedPubMedCentral
46.
Pathy NB, Verkooijen HM, Taib NA, et al. Impact of breast surgery on survival in women presenting with metastatic breast cancer. Br J Surg. 2011;98:1566–72.CrossRefPubMed
47.
Perez-Fidalgo JA, Pimentel P, Caballero A, et al. Removal of primary tumor improves survival in metastatic breast cancer. Does timing of surgery influence outcomes? Breast. 2011;20:548–54.CrossRefPubMed
48.
Rao R, Feng L, Kuerer HM, et al. Timing of surgical intervention for the intact primary in stage IV breast cancer patients. Ann Surg Oncol. 2008;15:1696–702.CrossRefPubMed
49.
Rapiti E, Verkooijen HM, Vlastos G, et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol. 2006;24:2743–9.CrossRefPubMed
50.
Rashaan ZM, Bastiaannet E, Portielje JE, et al. Surgery in metastatic breast cancer: patients with a favorable profile seem to have the most benefit from surgery. Eur J Surg Oncol. 2012;38:52–6.CrossRefPubMed
51.
Ruiterkamp J, Ernst MF, van de Poll-Franse LV, et al. Surgical resection of the primary tumour is associated with improved survival in patients with distant metastatic breast cancer at diagnosis. Eur J Surg Oncol. 2009;35:1146–51.CrossRefPubMed
52.
Shien T, Kinoshita T, Shimizu C, et al. Primary tumor resection improves the survival of younger patients with metastatic breast cancer. Oncol Rep. 2009;21:827–32.PubMed
53.
54.
AlJohani B, AlMalik O, Anwar E, et al. Impact of surgery on survival in stage IV breast cancer. Breast J. 2016;22:678–82.CrossRefPubMed
55.
Warschkow R, Guller U, Tarantino I, et al. Improved survival after primary tumor surgery in metastatic breast cancer: a propensity-adjusted, population-based SEER trend analysis. Ann Surg. 2016;263:1188–98.CrossRefPubMed
56.
Harano K, Lei X, Gonzalez-Angulo AM, et al. Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2016;159:367–74.CrossRefPubMed
57.
Thomas A, Khan SA, Chrischilles EA, Schroeder MC. Initial surgery and survival in stage IV breast cancer in the United States, 1988-2011. JAMA Surg. 2016;151:424–31.CrossRefPubMed
58.
Quinn EM, Kealy R, O'Meara S, et al. Is there a role for locoregional surgery in stage IV breast cancer? Breast. 2015;24:32–7.CrossRefPubMed
59.
van de Water W, Bastiaannet E, Egan KM, et al. Management of primary metastatic breast cancer in elderly patients—an international comparison of oncogeriatric versus standard care. J Geriatr Oncol. 2014;5:252–9.CrossRefPubMedPubMedCentral
60.
Samiee S, Berardi P, Bouganim N, et al. Excision of the primary tumour in patients with metastatic breast cancer: a clinical dilemma. Curr Oncol. 2012;19:e270–9.CrossRefPubMedPubMedCentral
61.
McGuire KP, Eisen S, Rodriguez A, et al. Factors associated with improved outcome after surgery in metastatic breast cancer patients. Am J Surg. 2009;198:511–5.CrossRefPubMed
62.
Nguyen DH, Truong PT, Alexander C, et al. Can locoregional treatment of the primary tumor improve outcomes for women with stage IV breast cancer at diagnosis? Int J Radiat Oncol Biol Phys. 2012;84:39–45.CrossRefPubMed
63.
Lang JE, Tereffe W, Mitchell MP, et al. Primary tumor extirpation in breast cancer patients who present with stage IV disease is associated with improved survival. Ann Surg Oncol. 2013;20:1893–9.CrossRefPubMedPubMedCentral
64.
Briasoulis E, Karavasilis V, Kostadima L, et al. Metastatic breast carcinoma confined to bone: portrait of a clinical entity. Cancer. 2004;101:1524–8.CrossRefPubMed
65.
Sherry MM, Greco FA, Johnson DH, Hainsworth JD. Metastatic breast cancer confined to the skeletal system. An indolent disease. Am J Med. 1986;81:381–6.CrossRefPubMed
66.
• Badwe R, Hawaldar R, Nair N, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol. 2015;16:1380–8. This is the first published randomized controlled trial evaluating the survival benefit of locoregional therapy for the primary tumor in patients with de novo metastatic breast cancer. Locoregional therapy for the primary tumor did not result in improved overall survival and was associated with shorter distant progression-free survival. CrossRefPubMed
67.
• Soran A, Ozmen V, Ozbas S et al A randomized controlled trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer: Turkish study (protocol MF07-01). J Clin Oncol 2016;34(suppl):abstr 1005. The unpublished results of this multicenter randomized trial demonstrated a survival benefit associated with local therapy for the primary tumor at a median of 40 months follow-up. The surgery group, however, may have been weighted towards more favorable disease characteristics.
68.
Soran A, Ozmen V, Ozbas S et al Early follow up of a randomized trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer; Turkish study (protocol MF07-01). Cancer Res 2013;73(24 Suppl):Abstract nr S2–03.
69.
• King TA, Lyman J, Gonen M et al A prospective analysis of surgery and survival in stage IV breast cancer (TBCRC 013). J Clin Oncol 2016;34(suppl):abstr 1006. This multicenter prospective registry trial evaluating the role of surgery for the primary tumor in de novo stage IV disease demonstrated that surgery did not impact overall survival among patients with an intact primary who responded to first-line systemic therapy.
Metadaten
Titel
New Insights on the Role of Surgery for the Breast Primary Tumor in Patients Presenting With Stage IV Disease
verfasst von
Anvy Nguyen
Tari A. King
Publikationsdatum
18.04.2017
Verlag
Springer US
Erschienen in
Current Breast Cancer Reports / Ausgabe 2/2017
Print ISSN: 1943-4588
Elektronische ISSN: 1943-4596
DOI
https://doi.org/10.1007/s12609-017-0241-z

Weitere Artikel der Ausgabe 2/2017

Current Breast Cancer Reports 2/2017 Zur Ausgabe

Invited Commentary

Targeting HER2/3 in Breast Cancer

Psycho-Oncology and Supportive Care (E Shinn and C Fagundes, Section Editors)

Treatment Decisions and Adherence to Adjuvant Endocrine Therapy in Breast Cancer

Psycho-Oncology and Supportive Care (E Shinn and C Fagundes, Section Editors)

Caregiving Stress and Its Toll on Health From a Psychoneuroimmunological Perspective

Local-Regional Evaluation and Therapy (EP Mamounas, Section Editor)

New Guidelines on the Adequacy of Lumpectomy Margin Width in Patients with Ductal Carcinoma In Situ

Local-Regional Evaluation and Therapy (EP Mamounas, Section Editor)

Diagnostic Methods, Risk Factors, Prevention, and Management of Breast Cancer-Related Lymphedema: Past, Present, and Future Directions

Psycho-Oncology and Supportive Care (E Shinn and C Fagundes, Section Editors)

Mechanisms of Neurotoxic Symptoms as a Result of Breast Cancer and Its Treatment: Considerations on the Contribution of Stress, Inflammation, and Cellular Bioenergetics

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise